Stockreport

Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study

Myovant Sciences Ltd. Common Shares  (MYOV) 
Last myovant sciences ltd. common shares earnings: 2/10 08:30 am Check Earnings Report
US:NYSE Investor Relations: investors.myovant.com
PDF Co-primary endpoints met with 75.2% response rate for dysmenorrhea (menstrual pain) (p and 66.0% response rate for non-menstrual pelvic pain (p Women receiving relugoli [Read more]